Novel therapies for chronic myelogenous leukemia

Slides:



Advertisements
Similar presentations
Insights into normal cell biology Targets for diagnosis and follow-up
Advertisements

Human T Cell Leukemia Virus Type 1 Oncoprotein Tax Targets the Human Mitotic Checkpoint Protein MAD1 Dong-Yan Jin, Forrest Spencer, Kuan-Teh Jeang Cell.
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich 
BRAF inhibitor: targeted therapy in hairy cell leukemia
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Volume 100, Issue 1, Pages (January 2000)
HER2/HER3 heterodimers in prostate cancer
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Luis A. Carvajal, Ulrich Steidl  Cell Stem Cell 
Cassie J. Clarke, Tessa L. Holyoake  Experimental Hematology 
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment  Tao Xu, Hongxiang Wang, Xiaoquan Huang, Weiqing Li, Qilin.
Extracellular Regulation of Apoptosis
Kinase inhibitors: Vice becomes virtue
Volume 120, Issue 1, Pages (January 2001)
Cell signaling and cancer
Nat. Rev. Urol. doi: /nrurol
Volume 11, Issue 3, Pages (September 2012)
Targeted Therapies in Melanoma: Translational Research at Its Finest
Mak Shu Ting (18) Yip Pui Yue (29)
Miki Ando, Hiromitsu Nakauchi  Experimental Hematology 
Ya-Huei Kuo, Jing Qi, Guerry J. Cook  Experimental Hematology 
Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors  Vivek Roy, Catherine M Verfaillie 
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Peter J. Nelson, Thomas O. Daniel  Kidney International 
Apoptosis-targeted therapies for cancer
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Philip A. Rascoe, MD, Xiaobo Cao, MD, Jonathan C. Daniel, MD, Steven D
Volume 20, Issue 1, Pages 3-5 (July 2011)
Keiran S.M. Smalley  Journal of Investigative Dermatology 
Vascular Endothelial Growth Factor (VEGF) Pathway
Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway
Targeting β-catenin in CML: Leukemia Stem Cells Beware!
Volume 14, Issue 6, Pages (December 2008)
A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia  Daniela Senft, Irmela Jeremias  Experimental.
Cellular signalling: Stressing the importance of PIP3
Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia  Michelle L. Churchman, Charles G. Mullighan 
The RAF Inhibitor Paradox Revisited
MicroRNAs: From Decay to Decoy
Experimental Hematology
Volume 82, Issue 11, Pages (December 2012)
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
Molecular Monitoring of Chronic Myeloid Leukemia
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich 
Translating Inflammatory Bowel Disease Research into Clinical Medicine
p38δ and PKD1: Kinase Switches for Insulin Secretion
Exploring the Neighborhood
aSIRTing Control over Cancer Stem Cells
Apoptosis-targeted therapies for cancer
Timothy R. Donahue, David W. Dawson  Cell Stem Cell 
The suppressors of cytokine signaling (SOCS) proteins
Volume 40, Issue 1, Pages (January 2004)
EMT and proteinuria as progression factors
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Kinase signaling and targeted therapy for primary myelofibrosis
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia  Raquel Vinhas, Alexandra R.
Regina M. Vidaver, PhD, Beth S. Schachter, PhD 
The new kid on the block(ade) of the IGF-1 receptor
Volume 1, Issue 3, Pages (April 2002)
Focus on head and neck cancer
ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity
Regulation of Angiogenesis and Tumorigenesis by Signal Transduction Cascades: Lessons from Benign and Malignant Endothelial Tumors  Robert Klafter, Jack.
Matthew I. Stein, Jiang Zhu, Stephen G. Emerson 
Attacking Cancer at Its Root
c-Raf in KRas Mutant Cancers: A Moving Target
Characterization of the MM.1 human multiple myeloma (MM) cell lines
Successful targeting of ErbB2 receptors—is PTEN the key?
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
Knocking the Wnt out of the Sails of Leukemia Stem Cell Development
Presentation transcript:

Novel therapies for chronic myelogenous leukemia Balkrishna N Jahagirdar, Jeffrey S Miller, Arun Shet, Catherine M Verfaillie  Experimental Hematology  Volume 29, Issue 5, Pages 543-556 (May 2001) DOI: 10.1016/S0301-472X(01)00633-6

Figure 1 Signal transduction pathways affected by the p210BCR-ABL oncoprotein. Activation of the Ras, Jak/Stat, and PI-3 kinase pathways results in increased proliferation, normal differentiation, and decreased apoptosis of the CML progenitors. The FAK-Paxillin-F-actin-integrin pathway impairs adhesion to the marrow stroma and causes premature release of the CML progenitors into the circulation. STK = Serine Threonine Kinase Experimental Hematology 2001 29, 543-556DOI: (10.1016/S0301-472X(01)00633-6)

Figure 2 Targets of novel therapies for CML. Antisense oligonucleotides inhibit translation. Immunotherapies evoke responses against the p210BCR-ABL peptide. Tyrosine kinase (TK) inhibitors inhibit the TK function of p210BCR-ABL. Farnesyl transferase inhibitors inhibit activation of the Ras protein Experimental Hematology 2001 29, 543-556DOI: (10.1016/S0301-472X(01)00633-6)